Repositioning Candidate Details
| Candidate ID: | R0620 |
| Source ID: | DB04832 |
| Source Type: | approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Zimelidine |
| Synonyms: | (Z)-3-(4'-Bromophenyl)-3-(3''-pyridyl)dimethylallylamine; (Z)-zimelidine; cis-zimelidine; Zimeldine |
| Molecular Formula: | C16H17BrN2 |
| SMILES: | CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1 |
| Structure: |
|
| DrugBank Description: | Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. |
| CAS Number: | 56775-88-3 |
| Molecular Weight: | 317.23 |
| DrugBank Indication: | For the treatment of depression. |
| DrugBank Pharmacology: | Zimelidine was the first marketed selective serotonin reuptake inhibitor (SSRI) antidepressant. It is a pyridylallylamine, structurally different from other antidepressants. |
| DrugBank MoA: | The antidepressant actions of zimelidine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Zimelidine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. |
| Targets: | Sodium-dependent serotonin transporter; Amine oxidase [flavin-containing] B inhibitor; Amine oxidase [flavin-containing] A inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|